| A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow HE Mei, I Wirries, D Frölich, M Brisslert, C Giesecke, JR Grün, T Alexander, ... Blood, The Journal of the American Society of Hematology 125 (11), 1739-1748, 2015 | 168 | 2015 |
| Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study S Stoelben, W Arns, L Renders, J Hummel, A Mühlfeld, M Stangl, ... Transplant International 27 (1), 77-86, 2014 | 142 | 2014 |
| The need for minimization strategies: current problems of immunosuppression J Bamoulid, O Staeck, F Halleck, D Khadzhynov, S Brakemeier, M Dürr, ... Transplant International 28 (8), 891-900, 2015 | 126 | 2015 |
| Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients M Duerr, P Glander, F Diekmann, D Dragun, HH Neumayer, K Budde Clinical Journal of the American Society of Nephrology 5 (4), 703-708, 2010 | 88 | 2010 |
| COVID-19 pandemic and worldwide organ transplantation: a population-based study O Aubert, D Yoo, D Zielinski, E Cozzi, M Cardillo, M Dürr, ... The Lancet Public Health 6 (10), e709-e719, 2021 | 84 | 2021 |
| A randomized clinical trial of anti–IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection K Doberer, M Duerr, PF Halloran, F Eskandary, K Budde, H Regele, ... Journal of the American Society of Nephrology 32 (3), 708-722, 2021 | 82 | 2021 |
| Experience with belatacept rescue therapy in kidney transplant recipients S Brakemeier, D Kannenkeril, M Dürr, T Braun, F Bachmann, D Schmidt, ... Transplant International 29 (11), 1184-1195, 2016 | 57 | 2016 |
| In vivo haematopoietic activity is induced in neurosphere cells by chromatin‐modifying agents C Schmittwolf, N Kirchhof, A Jauch, M Dürr, F Harder, M Zenke, AM Müller The EMBO Journal 24 (3), 554-566, 2005 | 57 | 2005 |
| Review of bortezomib treatment of antibody-mediated rejection in renal transplantation NS Ejaz, RR Alloway, F Halleck, M Dürr, K Budde, ES Woodle Antioxidants & redox signaling 21 (17), 2401-2418, 2014 | 53 | 2014 |
| Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial F Eskandary, M Dürr, K Budde, K Doberer, R Reindl-Schwaighofer, ... Trials 20 (1), 1-13, 2019 | 50 | 2019 |
| Multifrequency magnetic resonance elastography for the assessment of renal allograft function SRM Garcia, T Fischer, M Dürr, E Gültekin, J Braun, I Sack, J Guo Investigative Radiology 51 (9), 591-595, 2016 | 46 | 2016 |
| Assessment of the kidney donor profile index in a European cohort LJ Lehner, A Kleinsteuber, F Halleck, D Khadzhynov, E Schrezenmeier, ... Nephrology Dialysis Transplantation 33 (8), 1465-1472, 2018 | 44 | 2018 |
| Dendritic cell–regulatory T‐cell interactions control self‐directed immunity C Lange, M Dürr, H Doster, A Melms, F Bischof Immunology and cell biology 85 (8), 575-581, 2007 | 44 | 2007 |
| Conversion to belatacept in maintenance kidney transplant patients: a retrospective multicenter European study A Darres, C Ulloa, S Brakemeier, C Garrouste, O Bestard, A Del Bello, ... Transplantation 102 (9), 1545-1552, 2018 | 42 | 2018 |
| Enteric-coated mycophenolate sodium K Budde, M Dürr, L Liefeldt, HH Neumayer, P Glander Expert opinion on drug safety 9 (6), 981-994, 2010 | 42 | 2010 |
| Biomarkers of over‐immunosuppression K Budde, M Matz, M Dürr, P Glander Clinical Pharmacology & Therapeutics 90 (2), 316-322, 2011 | 39 | 2011 |
| A preliminary reconstruction of the Proto-Mixtec tonal system M Dürr Indiana 11, 19-61, 1990 | 39 | 1990 |
| Exploring the complexity of death-censored kidney allograft failure M Mayrdorfer, L Liefeldt, K Wu, B Rudolph, Q Zhang, F Friedersdorff, ... Journal of the American Society of Nephrology 32 (6), 1513-1526, 2021 | 38 | 2021 |
| An evaluation of sirolimus in renal transplantation F Halleck, M Duerr, J Waiser, L Huber, M Matz, S Brakemeier, L Liefeldt, ... Expert opinion on drug metabolism & toxicology 8 (10), 1337-1356, 2012 | 38 | 2012 |
| Identification and therapeutic management of highly sensitized patients undergoing renal transplantation L Huber, N Lachmann, M Dürr, M Matz, L Liefeldt, HH Neumayer, ... Drugs 72, 1335-1354, 2012 | 38 | 2012 |
Klemens BuddeCharité Universitätsmedizin BerlinAdresse e-mail validée de charite.de
